Docstoc

Programa-PCM-2011.docx - GABBA

Document Sample
Programa-PCM-2011.docx - GABBA Powered By Docstoc
					                                XX PORTO CANCER MEETING PROGRAM


DAY ONE: From the clinic to molecular targets (Sessions I and II)


8:00 Registration


8:45   Welcome: Manuel Sobrinho Simões (IPATIMUP and FMUP), Madalena Pinto (CEQUIMED-UP
and FFUP), Charles Swanton (CRUK and Royal Marsden Hospital), M. Helena Vasconcelos (FFUP and
IPATIMUP)




I – Mechanisms of drug resistance and identification of novel targets
Chairs: José E. Guimarães and Manuel Sobrinho-Simões


9:00-9:40 Hermann Lage – Charité, Institute of Pathology, Berlin, Germany
“An overview of cancer multidrug resistance: a still unsolved problem”


9:40-10:20 Jean-Pierre Marie - University Pierre & Marie Curie and Saint Antoine Hospital, Paris, France
“Pgp as a resistance factor in AML”


10:20-10:50 Coffee break


10:50-11:30 Charles Swanton, CR-UK Translational Cancer Therapeutics Laboratory,
London Research Institute and Royal Marsden Hospital, London, UK
“Integrative genomics strategies to identify novel drug resistance mechanisms in cancer”


11:30-12:10 Fernando Schmitt – IPATIMUP and FMUP, Porto, Portugal
"One size does not fit all! Finding therapeutic targets for subgroups of breast cancers"


12:10-14:10 Lunch break and poster session I (Translational Research posters)


II –Translating drug resistance research into patient stratification and personalised medicine
Chairs: Luís Costa and Charles Swanton
14:10-14:50 Junia V. Melo - University of Adelaide, Department of Haematology, Centre for Cancer
Biology - Adelaide, Australia
“Diagnosing, predicting and overcoming resistance to imatinib in chronic myeloid leukaemia”


14:50-15:30 Andrea L. Richardson – Harvard Medical School and Brigham and Women’s Hospital and
Dana-Farber Cancer Institute, Boston, MA, USA
“Molecular alterations in breast cancer pathobiology: guides for treatment choices”


15:30-16:10 Christos Sotiriou – Institut Jules Bordet, Brussels, Belgium
“Genomics and molecular biology in breast cancer: implications for treatment choices and drug
development”
16:10-16:40 Coffee break


16:40-17:20 Fabrice André, Institut Gustav Roussy, Villejuif, France
“Molecular targets in breast cancer to reverse drug resistance”


17:20-18:00 Dean Fennell- Cancer Research Centre, University of Belfast, Belfast, UK
“Targeting cell death pathways in thoracic malignancy”


20:00 Meeting Dinner




DAY TWO: Drug resistance, genome instability and tumour stem cells: therapeutic insights
(Sessions III and IV)


III– Drug resistance: impact of tumour somatic mutations and genome instability
Chairs: Raquel Seruca and Christos Sotiriou
9:00-9:40 Jorge S. Reis-Filho - The Breakthrough Breast Cancer Research Centre, Institute of Cancer
Research, London, UK
"BRCA1 and BRCA2 revertant mutations and resistance to therapy"


9:40-10:20 Jiri Bartek - Institute of Tumour Biology of the Danish Cancer Society,
Copenhagen, Denmark
“DNA damage response: Mechanisms and relevance for cancer development and treatment”


10:20-10:50 Coffee break


10:50-11:30 Alberto Inga - Centre for Integrative Biology, CIBIO, University of Trento, Trento, Italy
“Impact of distinct p53 mutations on cancer clinical variables”


11:.0-12:10 Zoltan Szallasi, Children's Hospital, Boston, USA and Technical University of Denmark,
Lyngby, Denmark
“Genome instability subtype and drug resistance: perspectives from the genomics analysis of breast
cancer”


12:10-12:50 Andy Futreal, Wellcome Trust Sanger Institute, Hinxton, UK
“Leveraging massively parallel sequencing in somatic cancer genetics”


12:50-14:50 Lunch break and poster session II (Basic Research posters)


IV –Targeting drug resistant disease
Chairs: M. Helena Vasconcelos and Dean Fennell
14:50-15:30 Cédric Blanpain, Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles
(ULB), Brussels, Belgium
“The role of cancer stem cells during cancer growth and relapse after therapy”


15:30-16:10 Klaus-Michael Debatin - University of Ulm, Ulm, Germany
“Cell death resistance in cancer”


16:10-16:50 Seamus J. Martin – Trinity College, Dublin, Ireland
“BH3-only proteins and cell death control”


16:50-17:20 Coffee break


17:20-18:00 Giovanni Gaudino – University of Hawaii Cancer Center, Honolulu, HI, USA
“Targeting survival and drug resistance in malignant mesothelioma”


18:00-18:40 Madalena M. M. Pinto, FFUP and CEQUIMED-UP, Portugal
“Multifunctional novel small-molecules to overcome drug resistance in cancer”


18:40 Adjourn: Charles Swanton (CRUK and Royal Marsden Hospital), M. Helena Vasconcelos (FFUP
and IPATIMUP), Madalena Pinto (CEQUIMED-UP and FFUP) and Manuel Sobrinho Simões
(IPATIMUP and FMUP)

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:9
posted:8/9/2011
language:English
pages:3